课题基金 / 基金详情

Mechanisms of viral proteases in coronavirus replication and pathogenesis

Mechanisms of viral proteases in coronavirus replication and pathogenesis
病毒蛋白酶在冠状病毒复制和发病机制中的机制
批准号:
9096719
负责人:
Susan C. Baker
金额:
$74.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2020-06-30

项目摘要

项目成果

Susan C. Baker的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): The goal of our research is to determine how viral proteases function in the replication and pathogenesis of coronaviruses (CoVs). CoVs are a family of positive strand RNA viruses and include Severe Acute Respiratory Syndrome (SARS) CoV and Middle East Respiratory Syndrome (MERS) CoV which are significant human pathogens with pandemic potential. Previously, we dissected the multifunctional nature of CoV papain-like proteases (PLPs) and found that CoV PLPs cleave the viral replicase polyprotein, act as deubiquitinases (DUBs) and deISGylases (deISGs) by removing ubiquitin (Ub) or ISG15 conjugated to lysine residues on proteins, and that PLPs can antagonize the innate immune response, likely by deubiquitylating signaling molecules. Using detailed biochemical and PLP-Ub co-crystal structural analysis, we identified residues within CoV PLPs that differentially affec enzymatic activity in vitro and in cell-based assays. Our initial studies were performed using SARS-CoV PLpro. Here we provide preliminary in vitro and structural data demonstrating that these results can be extended to the BSL-2 model coronavirus mouse hepatitis virus (MHV-A59) papain-like protease. We hypothesize that multifunctional PLP/DUB activity contributes to viral pathogenesis and that selectively disrupting DUB activity will allow activation of innate immunity and reduced viral pathogenesis. To test this hypothesis, we will determine if a modified PLP/DUB enzymatic activity alters viral replication, innate immune response or pathogenesis. We will use reverse genetics to generate murine CoVs encoding PLPs with distinct enzymatic profiles such as DUB deficient, deISGylation deficient, or hyperactive protease. These novel viruses will be evaluated in cell culture and in mice for kinetics of viral RNA synthesis, production of infectious virus, and kinetics of activation of innate immune responses. To extend these studies to other CoVs, we will determine the enzymatic profile (EP) and enzymatic fingerprint (EF) of alpha- and beta-CoV papain-like proteases including bat CoV PLPs. We will express the PLP domain from 10 different CoV species and determine the peptide cleavage activity, deubiquitinating activity, deISGylating activity, and lysine-linkage preferences for each enzyme. With this profile in hand, we will use existing and new X-ray structures combined to guide mutagenesis experiments to differentially disrupt DUB activity and identify the fingerprint associated with reduced DUB activity. We will also determine the role of differential activity in regulating the innate immune response in bat cells. Also, we identified an interaction of the CoV ADP-ribose-1"-phosphatase (ADRP) domain with PLP and we will determine the effect of modifying this interaction on enzymatic activity, viral replication and pathogenesis. These studies will reveal new information on viral protease/DUB activity that will be useful for designing antiviral therapies and vaccines for coronaviruses and other protease/DUB-encoding viruses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2
  • 批准号:
    10206579
  • 项目类别:
  • 资助金额:
    $78.99万
  • 财政年份:
    2021
  • 负责人:
    Susan C. Baker
  • 依托单位:
Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2
  • 批准号:
    10882676
  • 项目类别:
  • 资助金额:
    $10.55万
  • 财政年份:
    2021
  • 负责人:
    Susan C. Baker
  • 依托单位:
Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2
  • 批准号:
    10449132
  • 项目类别:
  • 资助金额:
    $75.05万
  • 财政年份:
    2021
  • 负责人:
    Susan C. Baker
  • 依托单位:
Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2
  • 批准号:
    10657457
  • 项目类别:
  • 资助金额:
    $74.92万
  • 财政年份:
    2021
  • 负责人:
    Susan C. Baker
  • 依托单位:
海外基金